Literature DB >> 20536260

Enabling the intestinal absorption of highly polar antiviral agents: ion-pair facilitated membrane permeation of zanamivir heptyl ester and guanidino oseltamivir.

Jonathan M Miller1, Arik Dahan, Deepak Gupta, Sheeba Varghese, Gordon L Amidon.   

Abstract

Antiviral drugs often suffer from poor intestinal permeability, preventing their delivery via the oral route. The goal of this work was to enhance the intestinal absorption of the low-permeability antiviral agents zanamivir heptyl ester (ZHE) and guanidino oseltamivir (GO) utilizing an ion-pairing approach, as a critical step toward making them oral drugs. The counterion 1-hydroxy-2-naphthoic acid (HNAP) was utilized to enhance the lipophilicity and permeability of the highly polar drugs. HNAP substantially increased the log P of the drugs by up to 3.7 log units. Binding constants (K(11(aq))) of 388 M(-1) for ZHE-HNAP and 2.91 M(-1) for GO-HNAP were obtained by applying a quasi-equilibrium transport model to double-reciprocal plots of apparent octanol-buffer distribution coefficients versus HNAP concentration. HNAP enhanced the apparent permeability (P(app)) of both compounds across Caco-2 cell monolayers in a concentration-dependent manner, as substantial P(app) (0.8-3.0 x 10(-6) cm/s) was observed in the presence of 6-24 mM HNAP, whereas no detectable transport was observed without counterion. Consistent with a quasi-equilibrium transport model, a linear relationship with slope near 1 was obtained from a log-log plot of Caco-2 P(app) versus HNAP concentration, supporting the ion-pair mechanism behind the permeability enhancement. In the rat jejunal perfusion assay, the addition of HNAP failed to increase the effective permeability (P(eff)) of GO. However, the rat jejunal permeability of ZHE was significantly enhanced by the addition of HNAP in a concentration-dependent manner, from essentially zero without HNAP to 4.0 x 10(-5) cm/s with 10 mM HNAP, matching the P(eff) of the high-permeability standard metoprolol. The success of ZHE-HNAP was explained by its >100-fold stronger K(11(aq)) versus GO-HNAP, making ZHE-HNAP less prone to dissociation and ion-exchange with competing endogenous anions and able to remain intact during membrane permeation. Overall, this work presents a novel approach to enable the oral delivery of highly polar antiviral drugs, and provides new insights into the underlying mechanisms governing the success or failure of the ion-pairing strategy to increase oral absorption.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20536260      PMCID: PMC3496398          DOI: 10.1021/mp100050d

Source DB:  PubMed          Journal:  Mol Pharm        ISSN: 1543-8384            Impact factor:   4.939


  32 in total

Review 1.  Drug-like properties and the causes of poor solubility and poor permeability.

Authors:  C A Lipinski
Journal:  J Pharmacol Toxicol Methods       Date:  2000 Jul-Aug       Impact factor: 1.950

Review 2.  The war against influenza: discovery and development of sialidase inhibitors.

Authors:  Mark von Itzstein
Journal:  Nat Rev Drug Discov       Date:  2007-12       Impact factor: 84.694

Review 3.  Prediction of solubility and permeability class membership: provisional BCS classification of the world's top oral drugs.

Authors:  Arik Dahan; Jonathan M Miller; Gordon L Amidon
Journal:  AAPS J       Date:  2009-10-30       Impact factor: 4.009

4.  The synthesis and enzymatic incorporation of sialic acid derivatives for use as tools to study the structure, activity, and inhibition of glycoproteins and other glycoconjugates.

Authors:  R Martin; K L Witte; C H Wong
Journal:  Bioorg Med Chem       Date:  1998-08       Impact factor: 3.641

Review 5.  Hydrophobic ion pairing: altering the solubility properties of biomolecules.

Authors:  J D Meyer; M C Manning
Journal:  Pharm Res       Date:  1998-02       Impact factor: 4.200

6.  Synthesis of 6-acetamido-5-amino- and -5-guanidino-3, 4-dehydro-N-(2-ethylbutyryl)- 3-piperidinecarboxylic acids related to zanamivir and oseltamivir, inhibitors of influenza virus neuraminidases.

Authors:  E Shitara; Y Nishimura; K Nerome; Y Hiramoto; T Takeuchi
Journal:  Org Lett       Date:  2000-11-30       Impact factor: 6.005

7.  HT29-MTX and Caco-2/TC7 monolayers as predictive models for human intestinal absorption: role of the mucus layer.

Authors:  C Pontier; J Pachot; R Botham; B Lenfant; P Arnaud
Journal:  J Pharm Sci       Date:  2001-10       Impact factor: 3.534

8.  Emergence of a novel swine-origin influenza A (H1N1) virus in humans.

Authors:  Fatimah S Dawood; Seema Jain; Lyn Finelli; Michael W Shaw; Stephen Lindstrom; Rebecca J Garten; Larisa V Gubareva; Xiyan Xu; Carolyn B Bridges; Timothy M Uyeki
Journal:  N Engl J Med       Date:  2009-05-07       Impact factor: 91.245

9.  Multiple efflux pumps are involved in the transepithelial transport of colchicine: combined effect of p-glycoprotein and multidrug resistance-associated protein 2 leads to decreased intestinal absorption throughout the entire small intestine.

Authors:  Arik Dahan; Hairat Sabit; Gordon L Amidon
Journal:  Drug Metab Dispos       Date:  2009-07-09       Impact factor: 3.922

10.  Segmental dependent transport of low permeability compounds along the small intestine due to P-glycoprotein: the role of efflux transport in the oral absorption of BCS class III drugs.

Authors:  Arik Dahan; Gordon L Amidon
Journal:  Mol Pharm       Date:  2009 Jan-Feb       Impact factor: 4.939

View more
  19 in total

Review 1.  Absorption enhancers: applications and advances.

Authors:  Bruce J Aungst
Journal:  AAPS J       Date:  2011-11-22       Impact factor: 4.009

2.  Carrier-Mediated Prodrug Uptake to Improve the Oral Bioavailability of Polar Drugs: An Application to an Oseltamivir Analogue.

Authors:  Tuba Incecayir; Jing Sun; Yasuhiro Tsume; Hao Xu; Tomoka Gose; Takeo Nakanishi; Ikumi Tamai; John Hilfinger; Elke Lipka; Gordon L Amidon
Journal:  J Pharm Sci       Date:  2016-02       Impact factor: 3.534

3.  Molecular basis for failure of "atypical" C1 domain of Vav1 to bind diacylglycerol/phorbol ester.

Authors:  Tamas Geczy; Megan L Peach; Saïd El Kazzouli; Dina M Sigano; Ji-Hye Kang; Christopher J Valle; Julia Selezneva; Wonhee Woo; Noemi Kedei; Nancy E Lewin; Susan H Garfield; Langston Lim; Poonam Mannan; Victor E Marquez; Peter M Blumberg
Journal:  J Biol Chem       Date:  2012-02-18       Impact factor: 5.157

4.  Regional-dependent intestinal permeability and BCS classification: elucidation of pH-related complexity in rats using pseudoephedrine.

Authors:  Moran Fairstein; Rotem Swissa; Arik Dahan
Journal:  AAPS J       Date:  2013-02-26       Impact factor: 4.009

5.  Development of oseltamivir phosphonate congeners as anti-influenza agents.

Authors:  Ting-Jen R Cheng; Steven Weinheimer; E Bart Tarbet; Jia-Tsrong Jan; Yih-Shyun E Cheng; Jiun-Jie Shie; Chun-Lin Chen; Chih-An Chen; Wei-Che Hsieh; Pei-Wei Huang; Wen-Hao Lin; Shi-Yun Wang; Jim-Min Fang; Oliver Yoa-Pu Hu; Chi-Huey Wong
Journal:  J Med Chem       Date:  2012-10-12       Impact factor: 7.446

6.  Pharmaceutical Co-Crystals, Salts, and Co-Amorphous Systems: A Novel Opportunity of Hot Melt Extrusion.

Authors:  Sagar Narala; Dinesh Nyavanandi; Priyanka Srinivasan; Preethi Mandati; Suresh Bandari; Michael A Repka
Journal:  J Drug Deliv Sci Technol       Date:  2020-11-09       Impact factor: 3.981

7.  Zanamivir oral delivery: enhanced plasma and lung bioavailability in rats.

Authors:  Srinivasan Shanmugam; Ho Taek Im; Young Taek Sohn; Kyung Soo Kim; Yong-Il Kim; Chul Soon Yong; Jong Oh Kim; Han-Gon Choi; Jong Soo Woo
Journal:  Biomol Ther (Seoul)       Date:  2013-03       Impact factor: 4.634

8.  Lipophilic Salts and Lipid-Based Formulations: Enhancing the Oral Delivery of Octreotide.

Authors:  Peng Li; Leigh Ford; Shadabul Haque; Mitchell P McInerney; Hywel D Williams; Peter J Scammells; Philip E Thompson; Vincent Jannin; Christopher J H Porter; Hassan Benameur; Colin W Pouton
Journal:  Pharm Res       Date:  2021-06-07       Impact factor: 4.200

9.  Permeability enhancers dramatically increase zanamivir absolute bioavailability in rats: implications for an orally bioavailable influenza treatment.

Authors:  Eric H Holmes; Harikrishna Devalapally; Libin Li; Michael L Perdue; Gary K Ostrander
Journal:  PLoS One       Date:  2013-04-17       Impact factor: 3.240

10.  Combined use of phospholipid complexes and self-emulsifying microemulsions for improving the oral absorption of a BCS class IV compound, baicalin.

Authors:  Huiyi Wu; Xiaoying Long; Fei Yuan; Li Chen; Sujing Pan; Yunjun Liu; Yoshiko Stowell; Xiaoling Li
Journal:  Acta Pharm Sin B       Date:  2014-04-29       Impact factor: 11.413

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.